1. Generics Bulletin
  2. >>Business
  3. >>Deals

Advanz Agrees Multi-Market Omalizumab Deal With Alvotech

Gains Rights To Market Xolair Biosimilar In Europe, Canada And Australiasia

 
• By Dave Wallace

Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.

Blue lungs with world map
Advanz has gained international rights to the asthma treatment • Source: Shutterstock

Advanz Pharma has struck a deal with Alvotech that will give it exclusive rights to register and market a biosimilar version of Novartis’s Xolair (omalizumab) asthma, rhinosinusitis and spontaneous urticaria treatment in multiple markets around the world.

While financial terms of the deal were not disclosed, Advanz specified that it would have “exclusive rights to register and commercialize” the omalizumab biosimilar in the European Economic Area, the UK, Switzerland, Canada, Australia,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.